MicroTao Biotech Secures Over RMB 100 Million in Series Angel Funding to Advance In Vivo CAR-T Therapy for Autoimmune Diseases

Nov 05, 2025 11:06 CST Updated 11:06

Vivacta

Cell Therapy Researcher

Recently, IVACTA Biotechnology (Shanghai) Co., Ltd. ("IVACTA Biotechnology" or "the Company"), a company focused on the field of in vivo cell therapy, announced that it has completed an angel round of financing exceeding RMB 100 million. The financing was led by Qiming Venture Partners, with participation from B Capital, Apricot Capital, and Shunxi Fund. The proceeds will mainly be used to advance the iterative upgrade of its core technology platform and accelerate the research and development process of its first candidate product for the treatment of autoimmune diseases.

IVACTA Biotechnology (Shanghai) Co., Ltd. was established in June 2025, spun off from Beijing Grail Biotherapeutics Co., Ltd. ("Grail Biotherapeutics") with its leading in vivo CAR-T technology platform. As an emerging force in the global in vivo cell therapy field, IVACTA Biotechnology focuses on the development of in vivo CAR-T therapies based on targeted lipid nanoparticle (LNP) delivery systems, committed to providing breakthrough treatment solutions for hematologic malignancies and autoimmune diseases.

Unlike traditional autologous CAR-T therapy, which involves a complex process of ex vivo T-cell collection, genetic modification, expansion, and reinfusion, IVACTA Biotechnology's in vivo CAR-T technology enables the in situ expression of CAR molecules directly within the patient’s T cells. This eliminates the need for cell separation, ex vivo expansion, and lymphodepletion pretreatment, fundamentally addressing the three major industry pain points of traditional CAR-T therapy: "high cost, long cycle, and significant toxicity." This technological approach not only has the potential to reduce the treatment cycle from weeks to days but also advances cell therapy from a highly personalized "custom-made treatment" toward standardized, scalable "off-the-shelf drugs," significantly improving the accessibility and affordability of treatment.

Currently, the global CAR-T industry is undergoing a leap from ex vivo to in vivo technological paradigms. In vivo CAR-T, with its potential to simplify processes, reduce costs, and enhance safety, is regarded as a key direction for the next generation of cell therapy. IVACTA Biotechnology has established a significant first-mover advantage in this field, with its self-developed targeted LNP delivery system demonstrating excellent performance in T-cell specificity, delivery efficiency, safety, and compatibility with production processes.

Notably, in recent years, several large pharmaceutical companies have shown strong interest in "in vivo CAR-T cell therapy," and this year, there have been multiple high-profile acquisition deals completed:AstraZenecaIn March, it acquired EsoBiotech for $1 billion; in June, AbbVie acquired for $2.1 billionCapstan Therapeutics；Gilead Sciences' Kite Pharma, on the other hand, acquired Interius BioTherapeutics for $350 million in August. With the shift in relevant policy directions and continuous technological breakthroughs, in vivo cell therapies, including in vivo CAR-T, are becoming the new frontier in the competition for the next generation of precision medicine.

E.N.D

ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe "Cell and Gene Therapy Field" team of the media platform WeChat Official Account has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following information when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also indicate.

SoundExplanation:ParticipateThe content is sourced from Qiming Venture Partners, IVACTA Biotechnology, and other sources.，ThisWenAiming atKnowledge Sharing, all content is for reference onlyFor reference only, not constituting any advice,If you have any questions about the content, please contactCell and Gene of the Official AccountTherapeutic Area GroupTeam,ContactEmail: cgtgeek1988@163.com。